Axsome Therapeutics Sets the Stage for Major Investor Events

Axsome Therapeutics Engages with Investors at Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical company focused on addressing central nervous system (CNS) disorders, is about to make its presence known at various important investor conferences. As the company leads the way in innovative treatment options, their upcoming appearances highlight both their commitment to advancing healthcare and their vision for the future.
Upcoming Conferences
With several events lined up for the month ahead, Axsome is ready to showcase its progress. Here is a look at the key conferences they will be attending:
Wells Fargo Healthcare Conference
The first stop is the 2025 Wells Fargo Healthcare Conference, where a fireside chat is scheduled for September 3, 2025. This presentation will take place in Boston at 3:45 p.m. ET. Investors will get insights into Axsome's strategies and further understanding of their innovative approaches.
Cantor Global Healthcare Conference
The following day, on September 4, Axsome will engage at the Cantor Global Healthcare Conference with a fireside chat at 1:00 p.m. ET in New York. This event provides a pivotal platform for discussing their ongoing projects and future potential with investors.
Morgan Stanley Annual Global Healthcare Conference
Continuing in New York, Axsome will be a part of the Morgan Stanley Annual Global Healthcare Conference on September 8. This chat is set for 2:35 p.m. ET, allowing attendees to dive deeper into Axsome's unique market position and product developments.
Baird Global Healthcare Conference
Axsome’s engagements will carry on with the Baird Global Healthcare Conference on September 10th at 3:10 p.m. ET, again in New York. This conference presents another opportunity to connect with key industry players and share their accomplishments.
TD Cowen Virtual Summit on Neuropsychiatry
Innovation knows no bounds for Axsome as they participate in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Virtual Summit on September 17. At 8:40 a.m. ET, this fireside chat will explore novel therapeutic approaches that Axsome is developing.
Deutsche Bank Virtual BioPharm Corporate Day
Wrapping up this month of investor engagement, Axsome will host investor meetings on September 18 during the Deutsche Bank Virtual BioPharm Corporate Day. This forum will ensure investors are briefed on the latest advancements and opportunities presented by the company.
Access to Presentations
For those unable to attend in person, Axsome will be making live webcasts available for the Wells Fargo, Cantor, Morgan Stanley, and TD Cowen conferences. Interested parties can access the webcasts via the “Webcasts & Presentations” section of Axsome’s corporate website. Replays will generally be available for about 30 days post-event, allowing for broader accessibility.
About Axsome Therapeutics
Axsome Therapeutics is working tirelessly to push the boundaries of treatment for CNS conditions. Their dedication involves not only identifying unmet needs in healthcare but also producing innovative solutions that enhance patient outcomes. The company has achieved significant milestones, boasting FDA-approved products for conditions such as major depressive disorder, excessive daytime sleepiness, obstructive sleep apnea, and migraines. Additionally, there are multiple late-stage programs aimed at tackling severe neurological and psychiatric ailments that affect millions in the United States.
Through a mix of expert knowledge and a strong determination to innovate, Axsome is on a mission to resolve some of the most challenging issues in neuroscience. The commitment to improving lives is evident in their daily operations and future projects.
For more details about Axsome Therapeutics, visit their website at www.axsome.com, where you can also find links to their updates on social media platforms like LinkedIn and X.
Frequently Asked Questions
What is Axsome Therapeutics known for?
Axsome Therapeutics specializes in the development of innovative treatments for central nervous system disorders, providing advances in several critical areas of healthcare.
When are the upcoming investor conferences for Axsome?
Axsome will participate in multiple conferences throughout September, including the Wells Fargo and Cantor conferences, among others.
How can I access the webcasts of Axsome’s presentations?
Webcasts of Axsome's presentations can be found on the 'Webcasts & Presentations' page of their corporate website.
What types of conditions does Axsome treat?
Axsome offers treatments for major depressive disorder, excessive daytime sleepiness, migraines, and various neurological and psychiatric disorders.
Who can I contact for investor relations at Axsome?
You can reach out to Ashley Dong, Director of Investor Relations, for inquiries at (929) 687-1614 or via email at adong@axsome.com.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.